KYSA-3

CD19-directed CAR T-cell therapy · Kyverna Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KYSA-3, covering 2025-10-29 to 2025-10-29. Get the full timeline:

Most recent: Clinical Trial Update: KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis [Phase 1, Phase 2]

See pricing